FDA Donor Rules: Why LGBTQ+ Patients Pay More for Sperm Banking

For same-sex male couples and many trans patients building families through assisted reproduction, the path to a biological child often runs through a sperm bank or fertility clinic that must follow United States Food and Drug Administration (FDA) tissue donor rules. Those rules, originally drafted to prevent transmission of HIV and other infections through donated tissue, end up classifying many committed partners as "anonymous" donors — triggering extra testing, extra quarantine time, and extra out-of-pocket costs that opposite-sex couples almost never face.

A 2024 paper in the journal LGBT Health by Dr. Joshua Shin, Dr. Martin Kathrins (a urologist at Brigham and Women's Hospital), and Dr. Alex Keuroghlian (a psychiatrist at Massachusetts General Hospital) laid out the problem in unusually concrete terms (PMID 38557157). Their argument, summarized in the public Mass General Brigham release that accompanied the paper, is that current FDA donor categories were built around an outdated risk model and now function as a financial penalty on LGBTQ+ family building.

This guide walks through how the three FDA donor categories actually work in a clinic, why same-sex male couples so often end up in the most expensive bucket, what hospital policies make the problem worse, and what reform proposals are on the table. We also compare the US framework to Canada's Assisted Human Reproduction (AHR) Act rules, which give known and directed donors more room to participate without the same financial drag.

The Three FDA Donor Categories

Under 21 CFR Part 1271, any sperm intended for use in a person who is not the donor's "sexually intimate partner" is regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps). In practice, US sperm banks and fertility clinics sort donors into three working categories:

• Anonymous donor. Sperm purchased from a commercial bank where the recipient does not personally know the donor. Full FDA donor eligibility testing is required, plus a six-month quarantine of frozen samples and repeat infectious disease testing before release.
• Directed (known) donor. A donor specifically chosen by the recipient — for example, a friend acting as a known sperm donor for a single mother by choice. Full FDA donor eligibility testing is still required, and most clinics also require a six-month quarantine and repeat testing.
• Sexually intimate partner. A donor whose sperm is used to conceive a child with their own sexually intimate partner. This category is exempt from the formal FDA donor eligibility testing requirements; routine pre-treatment infectious disease screening still applies, but the additional donor workup and quarantine are not required.

That third category is the one that matters financially. An opposite-sex couple using the male partner's sperm for in vitro fertilization (IVF) or intrauterine insemination (IUI) typically falls into the "sexually intimate partner" bucket and avoids the donor workup entirely.

A same-sex male couple where one partner's sperm will be used with an egg donor and gestational carrier — even if the two men are married and have been together for years — generally does not, because the sperm is destined for use in a third party (the gestational carrier). The same is often true for trans women using previously banked sperm with a cisgender female partner, depending on how the clinic interprets the rule.

Why LGBTQ+ Patients End Up in the Most Expensive Bucket

In the LGBT Health paper, Shin, Kathrins, and Keuroghlian point out that the FDA framework was designed around a model of donation from strangers, not around modern family building where the "donor" is often a known, committed partner. The result is that same-sex male couples and many trans patients get pushed into either the anonymous-equivalent or directed-donor pathway, both of which require the full donor workup.

That workup typically includes:

• A detailed donor risk-assessment interview covering sexual history, travel, and behavioral risk factors.
• Infectious disease testing for HIV-1/2, hepatitis B and C, syphilis, HTLV-I/II, CMV, and, for anonymous bank donors, chlamydia and gonorrhea.
• A six-month frozen quarantine of the sperm, followed by repeat infectious disease testing before the sample can be released for use.
• Genetic carrier screening and, at many programs, an additional psychological evaluation for the donor.

Clinics and patient advocates have long reported that the combined cost of directed donor screening — lab work, counselor visits, repeat draws, storage, and administrative fees — generally adds roughly $1,000 to $3,000 to the price of a cycle when the donor is a known person rather than a commercial bank purchase. That is on top of the underlying cost of IUI (often $300–$1,000 per cycle in the US) or IVF (commonly $15,000–$25,000 per cycle before medications, per published clinic ranges).

For a same-sex male couple already paying for egg donation and gestational surrogacy — typically a $100,000-plus journey in the United States — an extra few thousand dollars in donor screening is not abstract. It is the difference between affording one cycle and affording two.

Ready to compare programs that handle directed donor screening transparently? Start with the Fertility Link Navigator to see which clinics in your region accept directed donors without forcing you into the anonymous pathway.

Hospital Policies That Make It Worse

The FDA rules are only half the story. Many hospital-based fertility centers, especially academic programs, have internal policies that simply do not accommodate directed sperm donation at all. The reasons vary — risk management, lab workflow, infectious disease committee approvals — but the effect on patients is the same: a couple that wanted to use one partner's sperm with a gestational carrier is told the hospital cannot process that arrangement, and is referred to a private clinic that can.

Private clinics that do accept directed donors often charge a premium for the additional intake work, FDA paperwork, and quarantine storage. Patients who live in a region served primarily by a hospital-based program may have to travel to a different city, pay out-of-network rates, or coordinate shipping of frozen samples across state lines. Each of those steps adds cost and time.

The Shin, Kathrins, and Keuroghlian paper frames this as an equity problem: when the most accessible and often most affordable fertility programs in a region cannot serve LGBTQ+ patients on the same terms as opposite-sex couples, the FDA framework is effectively creating a two-tier system.

What Reform Could Look Like

The 2024 paper and the accompanying public statements from Mass General Brigham outline several reform directions. None is law yet, but each is being actively debated in reproductive medicine policy circles:

• An FDA equal-access mandate that would require clinics and tissue establishments to offer the sexually intimate partner pathway, or an equivalent, to committed same-sex partners and trans patients on the same terms as opposite-sex couples.
• Nuanced, individualized testing requirements based on the specific patient's history — including time in a monogamous relationship, prior testing, and PrEP use — rather than blanket category assignment.
• Updated donor categories that recognize "committed partner" arrangements outside of the strict sexually intimate partner definition, so that a married same-sex male couple using a gestational carrier is not treated identically to a stranger donating to a commercial bank.

In the Mass General Brigham release, Dr. Kathrins emphasized that the goal is not to lower safety standards but to align them with current evidence about transmission risk. Dr. Keuroghlian drew a direct parallel to the FDA's blood donation guidelines for men who have sex with men, which took, in his words, "several decades of advocacy" before the agency finally moved from a lifetime ban to a time-based deferral and, more recently, to individual risk assessment. The expectation is that tissue donor rules will follow a similar arc — just slowly.

How Canada Compares

Patients sometimes assume Canada is uniformly more restrictive than the US on assisted reproduction because of the Assisted Human Reproduction (AHR) Act's ban on paid donation. On the donor screening side, however, the Canadian framework is in some ways more flexible for known and directed donors.

Health Canada's Processing and Distribution of Semen for Assisted Conception Regulations and the AHR Act's directed donation provisions allow a known donor — for example, a friend acting as a sperm donor for a same-sex female couple — to go through a directed donor pathway with infectious disease testing but without the same commercial-bank quarantine model in every case. Clinics in Ontario, British Columbia, and Quebec routinely facilitate directed donor arrangements, and provincial funding programs such as the Ontario Fertility Program (OFP) cover the underlying cycle costs for eligible patients regardless of family structure.

The trade-off is that Canada prohibits payment to gamete donors, which limits the size of the donor pool and pushes some Canadian patients to import sperm from US banks anyway. But for an LGBTQ+ patient with a willing known donor, the Canadian framework is often the cheaper and faster path.

What This Means for You Right Now

If you are planning donor sperm treatment in 2026, a few practical takeaways:

• Ask the clinic which FDA category you fall into before you pay any intake fees. The category determines your testing bill.
• If you have a known donor, ask specifically whether the clinic supports directed donation in-house. Hospital-based programs that do not will often refer you out.
• Budget realistically for directed donor screening. Plan for $1,000–$3,000 in additional costs beyond the base cycle, and confirm whether quarantine storage is billed monthly.
• If you live near the border, compare Canadian directed-donor pathways. Provincial coverage and more flexible known-donor rules can offset travel costs for some patients.

For background on cycle pricing across both countries, see our add-on cost guide and the provincial program overview.

Get Your Personalized Roadmap

If you're navigating directed donor screening costs, register at The Fertility Link to filter clinics by FDA donor category support, compare directed-donor pricing across programs, and see your matches based on the family-building pathway you actually want to use.